VERU News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

VE

Mkt Cap

$39.3M

Volume

301.08K

Loading chart

VE

VERUVeru Inc.

VERU

Pay with—

Available Balance0.00

VE

Mkt Cap

$41.6M

Volume

301.08K

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

Veru Sells FC2 Condom Business For $18 Million, Focuses On Biopharma PipelineVeru sells its FC2 Female Condom business for $18 million, reducing its workforce by 90% and refocusing on its biopharma pipeline, including late-stage trials for enobosarm to treat weight loss in GLP-1-treated patients.Benzinga · Dec 31, 2024

Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) BusinessVeru Inc. has sold its FC2 Female Condom business for $18 million, allowing the company to focus on its late-stage biopharmaceutical pipeline, including a Phase 2b clinical trial evaluating enobosarm to preserve muscle and augment fat loss in patients receiving the GLP-1 receptor agonist Wegovy.GlobeNewswire Inc. · Dec 31, 2024

Sexual Wellness Market to Witness 4.7% CAGR by 2031 | SkyQuest TechnologyThe sexual wellness market is expected to grow at a CAGR of 4.7% by 2031, driven by increasing awareness of sexual health and the availability of a wide range of products. However, social stigma and regulatory challenges remain as key restraints.Benzinga · Oct 3, 2024

Veru to Participate in the Leerink Therapeutics Forum: I&I and MetabolismMIAMI, FL, July 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced the company will be participating in the Leerink Therapeutics Forum: I&I and Metabolism on July 9th, 2024, in Boston, Massachusetts.GlobeNewswire Inc. · Jul 2, 2024

Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific SessionsMIAMI, FL, June 24, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced data from two late-breaker presentations at the American Diabetes Association's 84th Scientific Sessions, which took place on June 21-24, 2024, in Orlando, Florida.GlobeNewswire Inc. · Jun 24, 2024

Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024MIAMI, FL, June 18, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that its Annual Meeting of Shareholders scheduled for today (Annual Meeting) was convened and adjourned without any business being conducted due to lack of a required quorum.GlobeNewswire Inc. · Jun 18, 2024

Veru Reminds Shareholders to Vote in Advance of Tomorrow’s Deadline for 2024 Annual Meeting of ShareholdersMIAMI, FL, June 17, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, would like to remind shareholders to vote in connection with the Company’s upcoming annual meeting of shareholders, to be held on Tuesday, June 18, 2024, at 9:00 AM ET. Shareholders are advised to vote their shares in advance of the proxy voting deadline of tomorrow, Tuesday, June 18, 2024, at 9:00 AM ET.GlobeNewswire Inc. · Jun 17, 2024

Veru to Present at the American Diabetes Association's 84th Scientific SessionsMIAMI, FL, June 10, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present two presentations at the American Diabetes Association's 84th Scientific Sessions, taking place June 21-24, 2024, in Orlando, Florida.GlobeNewswire Inc. · Jun 10, 2024

Veru to Present at the Jefferies Global Healthcare ConferenceMIAMI, FL, May 22, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present an update of Veru’s Phase 2b clinical program of enobosarm to augment fat loss and to avoid muscle loss when combined with GLP-1 drugs for weight loss at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:00 am – 11:25 am ET.GlobeNewswire Inc. · May 22, 2024

Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight LossMIAMI, FL, May 15, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced Steven B. Heymsfield, M.D., a Professor and the Director of the Body Composition-Metabolism Laboratory at the Pennington Biomedical Research Center in Baton Rouge, Louisiana, as the Principal Investigator for the Company’s Phase 2b clinical trial of enobosarm to preserve muscle while augmenting fat loss in patients receiving a GLP-1 RA for weight loss.GlobeNewswire Inc. · May 15, 2024

to start trading

VE

VERUVeru Inc.

VERU

Pay with—

Available Balance0.00

Your PositionYou don't own any VERU yet.

Related Tickers

Earnings